Wall Street analysts expect Acceleron Pharma Inc (NASDAQ:XLRN) to announce ($0.23) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Acceleron Pharma’s earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.35). Acceleron Pharma reported earnings per share of ($0.63) during the same quarter last year, which would indicate a positive year over year growth rate of 63.5%. The company is expected to issue its next quarterly earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Acceleron Pharma will report full year earnings of ($2.42) per share for the current fiscal year, with EPS estimates ranging from ($2.78) to ($1.98). For the next financial year, analysts expect that the company will post earnings of ($1.39) per share, with EPS estimates ranging from ($1.60) to ($1.17). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.07). Acceleron Pharma had a negative net margin of 965.39% and a negative return on equity of 35.94%. The business had revenue of $2.78 million during the quarter, compared to analyst estimates of $3.67 million. During the same quarter last year, the business posted ($0.58) earnings per share. The business’s quarterly revenue was down 13.9% compared to the same quarter last year.
In other Acceleron Pharma news, CFO Kevin F. Mclaughlin sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $44.62, for a total transaction of $535,440.00. Following the transaction, the chief financial officer now owns 30,379 shares in the company, valued at $1,355,510.98. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Habib J. Dable sold 7,460 shares of the firm’s stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $44.60, for a total value of $332,716.00. Following the transaction, the chief executive officer now owns 76,754 shares in the company, valued at approximately $3,423,228.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,730 shares of company stock worth $1,060,959. Company insiders own 2.50% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Voya Investment Management LLC boosted its holdings in Acceleron Pharma by 1.6% during the first quarter. Voya Investment Management LLC now owns 16,831 shares of the biopharmaceutical company’s stock worth $784,000 after buying an additional 257 shares during the last quarter. Comerica Bank boosted its holdings in Acceleron Pharma by 1.2% during the fourth quarter. Comerica Bank now owns 24,369 shares of the biopharmaceutical company’s stock worth $964,000 after buying an additional 290 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Acceleron Pharma by 13.7% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,958 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 356 shares during the last quarter. Knott David M boosted its holdings in Acceleron Pharma by 6.1% during the fourth quarter. Knott David M now owns 17,400 shares of the biopharmaceutical company’s stock worth $758,000 after buying an additional 1,000 shares during the last quarter. Finally, Clarfeld Financial Advisors LLC bought a new position in Acceleron Pharma during the fourth quarter worth about $44,000. Hedge funds and other institutional investors own 89.84% of the company’s stock.
Shares of NASDAQ:XLRN traded up $0.49 during midday trading on Friday, reaching $42.06. The company’s stock had a trading volume of 218,995 shares, compared to its average volume of 425,631. The firm has a market cap of $2.22 billion, a PE ratio of -16.24 and a beta of 1.31. Acceleron Pharma has a fifty-two week low of $32.53 and a fifty-two week high of $59.59. The company has a debt-to-equity ratio of 0.05, a quick ratio of 19.26 and a current ratio of 19.26.
Acceleron Pharma Company Profile
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.